Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic stem cell transplantation.

Godfrey J, Liu H, Yu J, Tallarico M, Curran E, Artz AS, Riedell PA, Stock W, Karrison T, Fitzpatrick C, et al. Pembrolizumab for the treatment of disease relapse following allogeneic hematopoietic stem cell transplantation. Blood Adv. 2022.